Fennec Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Fennec Pharmaceuticals has been growing earnings at an average annual rate of 21.5%, while the Biotechs industry saw earnings growing at 30% annually. Revenues have been growing at an average rate of 62% per year.
Key information
21.53%
Earnings growth rate
23.36%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 61.96% |
| Return on equity | -27.46% |
| Net Margin | -21.82% |
| Last Earnings Update | 31 Dec 2025 |
Recent past performance updates
Recent updates
FENC: Expanding Cisplatin Ototoxicity Use Should Support Future Bullish Earnings Multiple
Analysts have adjusted their price target on Fennec Pharmaceuticals to $18.00, with the change supported by updated assumptions around revenue growth, profit margins, and a future P/E of about 12.8, in line with a recently bullish initiation from Street research. Analyst Commentary Bullish analysts are framing the updated US$18.00 price target as consistent with expectations for Fennec Pharmaceuticals to execute against current revenue and margin assumptions while trading on a P/E of about 12.8. These views generally point to a setup where, if the company delivers on its plan, the current valuation case remains intact and could support the new target level.FENC: Cisplatin Ototoxicity Niche Will Support Future Bullish Earnings Multiple
Analysts have raised their price target on Fennec Pharmaceuticals to $18.00, supported by updated assumptions on revenue growth, profit margin and future P/E, and underpinned by a recent bullish initiation from B. Riley that reflects growing confidence in the company’s outlook.FENC: Cisplatin Ototoxicity Niche Will Underpin Future Supportive Care Upside
Analysts have reaffirmed an $18 price target for Fennec Pharmaceuticals, highlighting supportive research that emphasizes Pedmark's role as a unique, approved option in oncology supportive care. They are also reassessing assumptions related to future revenue growth, profit margins and P/E expectations.
FENC: Single Oncology Supportive Care Asset Will Drive Future Upside Potential
Narrative Update: Fennec Pharmaceuticals Analysts have lifted their price target on Fennec Pharmaceuticals from $14.00 to about $15.33, citing a richer revenue outlook, higher anticipated profit margins, and a willingness to apply a lower future P/E multiple. They highlight Pedmark's position as a unique, FDA approved option in oncology supportive care, with U.S. peak sales potential referenced above $300m.FENC: Cisplatin Ototoxicity Niche Will Support Future Oncology Care Upside
Analysts are reiterating an $18 price target for Fennec Pharmaceuticals. They point to updated assumptions that include slightly lower discount rates, higher projected revenue growth and profit margins, and a modestly lower future P/E, supported by recent bullish initiations that highlight Pedmark's role as a unique oncology supportive care opportunity.FENC: Cisplatin Ototoxicity Niche Will Drive Future Supportive Care Upside
Analysts have reiterated a US$18 price target on Fennec Pharmaceuticals, supported by their view that Pedmark offers a unique, only-approved option in oncology supportive care, with what they describe as realistic peak U.S. sales potential above US$300m. Analyst Commentary Recent coverage has centered on Pedmark as a key driver for Fennec's equity story, with bullish analysts highlighting its role as the only approved agent for reducing the risk of cisplatin induced ototoxicity in oncology supportive care.FENC: Cisplatin Ototoxicity Leadership And New Studies Will Support Strong Future Upside
Narrative Update Analysts are reaffirming a US$18 price target on Fennec Pharmaceuticals, pointing to Pedmark's role as the only approved agent for reducing cisplatin induced ototoxicity and noting that they view U.S. peak sales potential above US$300m as realistic. Analyst Commentary Bullish analysts are highlighting Fennec Pharmaceuticals as a focused oncology supportive care story, built around Pedmark as an intravenous formulation of sodium thiosulfate for reducing the risk of cisplatin induced ototoxicity.FENC: Unique Oncology Supportive Care Opportunity Will Drive Stronger Future Upside Potential
Narrative Update Overview Our fair value estimate for Fennec Pharmaceuticals edges up from $17 to $18 per share, reflecting analysts' view that Pedmark offers a unique oncology supportive care opportunity with U.S. peak sales potential cited north of $300 million and supports using a slightly higher revenue growth outlook, modestly stronger profit margins, and a lower future P/E multiple. Analyst Commentary Bullish analysts are centering their thesis on Pedmark as a differentiated oncology supportive care product, and that view is shaping how they think about valuation, execution risk, and long term growth potential.FENC: Expanded Adult Study Will Drive Stronger Future Upside Potential
Analysts have nudged their price target on Fennec Pharmaceuticals modestly higher to reflect slightly faster expected revenue growth, marginally improved profit margins, and a marginally lower projected future price to earnings multiple, supporting a fair value estimate of $17.00 per share. What's in the News Planned City of Hope investigator sponsored study will evaluate PEDMARK for preventing cisplatin induced hearing loss in adult men with stage II III metastatic testicular germ cell tumors, expanding its potential use beyond pediatrics (company announcement).Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026
Dec 22FENC: Expanded Hearing Loss Indication Will Drive Stronger Future Upside Potential
Analysts have raised their price target on Fennec Pharmaceuticals from 15 dollars to 17 dollars, citing updated assumptions for discount rates, growth, profitability, and valuation multiples that, despite being more conservative on margins and revenue growth, still imply a higher fair value. What's in the News City of Hope to launch an investigator sponsored study of PEDMARK in adult men with stage II III metastatic testicular germ cell tumors to prevent cisplatin induced hearing loss, expanding potential use beyond pediatrics (company announcement) Positive topline results reported from the Phase 2/3 STS J01 trial in Japan evaluating PEDMARK for reducing cisplatin induced ototoxicity in pediatric and AYA patients, with Fennec planning to pursue Japanese registration and potential partnering or licensing deals (company announcement) Completed 35 million dollar follow on equity offering of 4,666,667 common shares at 7.50 dollars per share, bolstering the balance sheet for commercialization and development initiatives (financing filing) Announced a non brokered private placement of 670,000 common shares at 7.50 dollars per share for expected gross proceeds of 5.0 million dollars, with closing targeted for November 17, 2025 (financing announcement) Lock up agreements put in place on over 28 million common shares and various equity linked awards through February 12, 2026, limiting insider and holder sales for 91 days after the November 13, 2025 offering (offering documentation) Valuation Changes Fair value estimate increased from 15 dollars to 17 dollars per share, implying a modest upward revision to intrinsic value despite more conservative operating assumptions.Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price Is Matching Sentiment Around Its Revenues
Apr 24
US$12.60: That's What Analysts Think Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Is Worth After Its Latest Results
Mar 13Improved Revenues Required Before Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock's 25% Jump Looks Justified
Nov 24Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price
Oct 04
Jeff Hackman's Leadership And PEDMARK's Launch Promise Robust Revenue Surge
Introduction of PEDMARK and strategic partnerships aim to boost net revenues through expanded patient access and improved distribution.Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be
Aug 15Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?
Jul 16Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop
Jun 02Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Apr 18Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates
Nov 09Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Fennec Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 45 | -10 | 47 | 0 |
| 30 Sep 25 | 39 | -7 | 41 | 0 |
| 30 Jun 25 | 33 | -12 | 39 | 0 |
| 31 Mar 25 | 31 | -14 | 39 | 0 |
| 31 Dec 24 | 48 | 0 | 41 | 0 |
| 30 Sep 24 | 49 | -1 | 44 | 0 |
| 30 Jun 24 | 49 | 3 | 41 | 0 |
| 31 Mar 24 | 45 | 3 | 37 | 0 |
| 31 Dec 23 | 21 | -16 | 33 | 0 |
| 30 Sep 23 | 13 | -20 | 29 | 0 |
| 30 Jun 23 | 7 | -26 | 29 | 1 |
| 31 Mar 23 | 3 | -26 | 25 | 2 |
| 31 Dec 22 | 2 | -24 | 21 | 4 |
| 30 Sep 22 | 0 | -21 | 17 | 4 |
| 30 Jun 22 | 0 | -17 | 13 | 4 |
| 31 Mar 22 | 0 | -16 | 12 | 4 |
| 31 Dec 21 | 0 | -17 | 12 | 5 |
| 30 Sep 21 | 0 | -16 | 11 | 6 |
| 30 Jun 21 | 0 | -18 | 12 | 6 |
| 31 Mar 21 | 0 | -19 | 13 | 6 |
| 31 Dec 20 | 0 | -18 | 13 | 5 |
| 30 Sep 20 | 0 | -18 | 13 | 5 |
| 30 Jun 20 | 0 | -14 | 10 | 4 |
| 31 Mar 20 | 0 | -14 | 9 | 5 |
| 31 Dec 19 | 0 | -13 | 7 | 6 |
| 30 Sep 19 | 0 | -12 | 6 | 6 |
| 30 Jun 19 | 0 | -13 | 6 | 7 |
| 31 Mar 19 | 0 | -11 | 5 | 6 |
| 31 Dec 18 | 0 | -10 | 5 | 5 |
| 30 Sep 18 | 0 | -9 | 6 | 4 |
| 30 Jun 18 | 0 | -9 | 6 | 3 |
| 31 Mar 18 | 0 | -8 | 6 | 2 |
| 31 Dec 17 | 0 | -7 | 5 | 2 |
| 30 Sep 17 | 0 | -6 | 4 | 1 |
| 30 Jun 17 | 0 | -4 | 3 | 1 |
| 31 Mar 17 | 0 | -3 | 3 | 1 |
| 31 Dec 16 | 0 | -3 | 2 | 0 |
| 30 Sep 16 | 0 | -2 | 2 | 0 |
| 30 Jun 16 | 0 | -2 | 2 | 0 |
| 31 Mar 16 | 0 | -1 | 2 | 0 |
| 31 Dec 15 | 0 | -1 | 2 | 0 |
| 30 Sep 15 | 0 | 1 | 2 | 0 |
Quality Earnings: FENC is currently unprofitable.
Growing Profit Margin: FENC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FENC is unprofitable, but has reduced losses over the past 5 years at a rate of 21.5% per year.
Accelerating Growth: Unable to compare FENC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FENC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (40.2%).
Return on Equity
High ROE: FENC has a negative Return on Equity (-27.46%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/04 20:39 |
| End of Day Share Price | 2026/05/04 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fennec Pharmaceuticals Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Naureen Quibria | Capital One Securities, Inc. |